PMID- 23939233
OWN - NLM
STAT- MEDLINE
DCOM- 20140707
LR  - 20240620
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 27
IP  - 17
DP  - 2013 Nov 13
TI  - Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV 
      controllers.
PG  - 2691-6
LID - 10.1097/01.aids.0000433242.86362.21 [doi]
AB  - OBJECTIVE: HIV controllers demonstrate high rates of spontaneous clearance of 
      hepatitis C virus (HCV) infection. The objective of this study was to evaluate 
      the role of human leukocyte antigen (HLA) B*57 and other genetic polymorphisms on 
      HCV clearance in HIV controllers. DESIGN: This is a prospective cohort study. 
      METHODS: Patients in the Study of the Consequences of Protease Inhibitor Era 
      (SCOPE) were tested for anti-HCV using enzyme immunoassay (EIA3) and HCV RNA 
      using discriminatory HCV transcription-mediated amplification assay (Norvatis). 
      We compared the proportion of HIV controllers and noncontrollers demonstrating 
      HCV clearance and fitted multivariable Poisson regression models with robust 
      standard errors to estimate adjusted prevalence ratios (APRs) and assessed 
      genetic and immunologic predictors of HCV clearance. RESULTS: Of 279 HIV/HCV 
      seropositive individuals, 48 were HIV controllers. HIV controllers compared to 
      HIV noncontrollers, were significantly more likely to have HLA B*57 (33 vs. 10%, 
      P < 0.01). In multivariate analyses, adjusting for HLAB57, IL28B genotype, age, 
      sex and race/ethnicity, HCV clearance was significantly more likely in HIV 
      controllers than HIV noncontrollers [APR 1.78; 95% confidence interval (CI) 
      1.06-3.0; P = 0.03]. HLA B*57 did not explain the increased proportion of HCV 
      clearance in HIV controllers, but IL28B CC genotype was independently associated 
      with spontaneous HCV clearance (APR 2.76; 95% CI 1.85-4.11; P < 0.001). 
      CONCLUSION: Although enriched in HIV controllers, HLA B*57 does not explain the 
      increased HCV clearance. Further identification of host immunologic or genetic 
      factors that contribute to control of HIV and HCV may support the development of 
      novel treatments for and effective vaccines against both viruses.
FAU - Asher, Alice K
AU  - Asher AK
AD  - aDepartment of Community Health Systems, School of Nursing, University of 
      California San Francisco bDepartment of Epidemiology & Biostatistics, University 
      of California San Francisco cDepartment of Medicine, University of California San 
      Francisco dBlood Systems Research Institute, San Francisco, California, USA.
FAU - Santos, Glenn-Milo
AU  - Santos GM
FAU - Evans, Jennifer
AU  - Evans J
FAU - Dokubo, Emily K
AU  - Dokubo EK
FAU - Lee, Tzong-Hae
AU  - Lee TH
FAU - Martin, Jeffrey N
AU  - Martin JN
FAU - Deeks, Steven G
AU  - Deeks SG
FAU - Tobler, Leslie H
AU  - Tobler LH
FAU - Busch, Michael
AU  - Busch M
FAU - Hunt, Peter W
AU  - Hunt PW
FAU - Page, Kimberly
AU  - Page K
LA  - eng
GR  - T32 MH019105/MH/NIMH NIH HHS/United States
GR  - R01 DA016017/DA/NIDA NIH HHS/United States
GR  - T32 MH-19105-21/MH/NIMH NIH HHS/United States
GR  - P30 AI027763/AI/NIAID NIH HHS/United States
GR  - P30 DK026743/DK/NIDDK NIH HHS/United States
GR  - T32 NR07081/NR/NINR NIH HHS/United States
GR  - 2 R01DA016017-03A1/DA/NIDA NIH HHS/United States
GR  - TL1 RR024129/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B57 antigen)
RN  - 0 (Hepatitis C Antibodies)
RN  - 0 (RNA, Viral)
SB  - IM
EIN - AIDS. 2014 Feb 20;28(4):619
CIN - AIDS. 2014 May 15;28(8):1241-2. doi: 10.1097/QAD.0000000000000208. PMID: 25028914
CIN - AIDS. 2014 May 15;28(8):1242-3. doi: 10.1097/QAD.0000000000000207. PMID: 25028915
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Gene Frequency
MH  - HIV Infections/*complications
MH  - *HIV Long-Term Survivors
MH  - HLA-B Antigens/*genetics/*immunology
MH  - Hepatitis C/*complications/*immunology
MH  - Hepatitis C Antibodies/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - RNA, Viral/blood
PMC - PMC4125012
MID - NIHMS611125
COIS- Conflicts: The authors declare that they have no commercial or other association 
      that might pose a conflict of interest with this research.
EDAT- 2013/08/14 06:00
MHDA- 2014/07/08 06:00
PMCR- 2014/08/07
CRDT- 2013/08/14 06:00
PHST- 2013/08/14 06:00 [entrez]
PHST- 2013/08/14 06:00 [pubmed]
PHST- 2014/07/08 06:00 [medline]
PHST- 2014/08/07 00:00 [pmc-release]
AID - 10.1097/01.aids.0000433242.86362.21 [doi]
PST - ppublish
SO  - AIDS. 2013 Nov 13;27(17):2691-6. doi: 10.1097/01.aids.0000433242.86362.21.